Detalhe da pesquisa
1.
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
Proc Natl Acad Sci U S A
; 121(17): e2321898121, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38625939
2.
Black-White differences in uterine cancer symptomatology and stage at diagnosis.
Gynecol Oncol
; 180: 118-125, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38091770
3.
Integrated mutational landscape analysis of uterine leiomyosarcomas.
Proc Natl Acad Sci U S A
; 118(15)2021 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33876771
4.
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Ann Surg Oncol
; 30(9): 5597-5609, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37358686
5.
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Gynecol Oncol
; 168: 157-165, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36442427
6.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Gynecol Oncol
; 170: 38-45, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36610380
7.
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Gynecol Oncol
; 170: 172-178, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706643
8.
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Gynecol Oncol
; 169: 98-105, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36525930
9.
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
Gynecol Oncol
; 172: 65-71, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36958197
10.
Changes to same day discharge after minimally invasive hysterectomy throughout COVID-19 pandemic.
J Obstet Gynaecol Res
; 49(5): 1418-1423, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36808793
11.
A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Cancer
; 128(6): 1206-1218, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34875107
12.
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Br J Cancer
; 126(12): 1695-1703, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35149854
13.
Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer.
Gynecol Oncol
; 167(3): 417-422, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37191644
14.
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
Gynecol Oncol
; 166(2): 351-357, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641325
15.
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Gynecol Oncol
; 166(1): 117-125, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35599167
16.
Endometrial Carcinoma as the Presenting Malignancy in a Teenager With a Pathogenic TP53 Germline Mutation: A Case Report and Literature Review.
Int J Gynecol Pathol
; 41(3): 258-267, 2022 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33990091
17.
Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
Gynecol Oncol
; 163(1): 209-214, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34325937
18.
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.
Gynecol Oncol
; 163(1): 93-99, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34372971
19.
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Gynecol Oncol
; 163(2): 334-341, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34452746
20.
Does Radical Hysterectomy for Clinically Apparent Stage II Endometrial Cancer Affect Risk of Local Recurrence?
J Obstet Gynaecol Can
; 43(5): 564-570, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33412305